Caixin Securities maintains WuXi AppTec’s recommendation rating: emerging business growth is good, 2022 performance is expected to accelerate target price 131.40-146.00 yuan_Oriental Fortune Network

financial lettersecuritiesPosted on March 24thResearch reportsay, maintainWuXi AppTec(603259.SH, latest price: 109.65 yuan) recommended rating, target price of 131.40-146.00 yuan. The reasons for the rating mainly include: 1) Chemical business: new business contributions such as oligonucleotide and peptide drugs, preparation CDMO, etc., are expected to increase by about 94.00% year-on-year in 2022; 2) Testing business: revenue in 2021 + + 38.03%, toxicology, clinical CRO, and SMO services are growing rapidly; 3) Biological business: new molecular species such as oligonucleotides and biopharmaceutical revenue have grown rapidly; 4) Cell and gene therapy CTDMO business: expected to welcome growth in 2022 5) Domestic new drug research and development services: Affected by the increase in research and development requirements, revenue growth is expected to be under pressure in 2022. Risk warning: risk of new crown epidemic, risk of intensified competition in the industry, risk of exchange rate changes, risk of Sino-US trade friction, risk of less than expected growth in orders, etc.

AI comments:WuXi AppTec19 copies in the past monthbrokerageThe research report paid attention to 17 companies with an average target price of 152.31 yuan, which was 42.66 yuan higher than the latest price of 109.65 yuan, and the average target price increased by 38.91%.

(Article source: Daily Economic News)

Article source: Daily Economic News

Responsible editor: 10

Original title: Caixin Securities maintains WuXi AppTec’s recommendation rating: emerging business growth is good, performance is expected to accelerate in 2022, target price 131.40-146.00 yuan